SEC Form 4 · accession 0000899243-18-019736
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara K Finck
Officer — Chief Medical Officer
Period of report
Jul 9, 2018
Accepted (ET)
Jul 11, 2018 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Jul 9, 2018 | M | 500 | $1.42 | A | 37,543 | D | |
| Common Stock, $0.0001 par value | Jul 9, 2018 | S | 500 | $15.03 | D | 37,043 | D | |
| Common Stock, $0.0001 par value | Jul 10, 2018 | M | 1,260 | $1.42 | A | 38,303 | D | |
| Common Stock, $0.0001 par value | Jul 10, 2018 | S | 1,260 | $15.00 | D | 37,043 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.42 | Jul 9, 2018 | M | 500 | D | — | Nov 23, 2023 | Common Stock | 500 | 87,721 | D |
| Stock Option (right to buy)F2 | $1.42 | Jul 10, 2018 | M | 1,260 | D | — | Nov 21, 2023 | Common Stock | 1,260 | 86,461 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- F2The shares underlying this option are fully vested and exercisable as of the date hereof.